OWCP (OWC Pharmaceutical Research) Ending Cash Position: $1.47 Mil (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research Ending Cash Position?

OWC Pharmaceutical Research OWCP -90.00% Ending Cash Position is $1.47 Mil as of Sep. 2019.

OWC Pharmaceutical Research's Ending Cash Position for the quarter that ended in Sep. 2019 was $1.47 Mil.

OWC Pharmaceutical Research's quarterly Ending Cash Position declined from Mar. 2019 ($2.80 Mil) to Jun. 2019 ($1.84 Mil) and declined from Jun. 2019 ($1.84 Mil) to Sep. 2019 ($1.47 Mil).

OWC Pharmaceutical Research's annual Ending Cash Position increased from Dec. 2016 ($0.47 Mil) to Dec. 2017 ($0.97 Mil) and increased from Dec. 2017 ($0.97 Mil) to Dec. 2018 ($3.46 Mil).

OWC Pharmaceutical Research Ending Cash Position Related Terms

OWC Pharmaceutical Research Ending Cash Position Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research Ending Cash Position Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 1.47 0.36 0.47 0.97 3.46

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.22 3.46 2.80 1.84 1.47

OWC Pharmaceutical Research Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

OWC Pharmaceutical Research's Ending Cash Position for the fiscal year that ended in Dec. 2018 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.971+2.493
=3.46

OWC Pharmaceutical Research's Ending Cash Position for the quarter that ended in Sep. 2019 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.84+-0.375
=1.47

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.47 Mil mean?
OWC Pharmaceutical Research (OWCP) has a Ending Cash Position of $1.47 Mil as of Sep. 2019. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's Ending Cash Position too high?
OWC Pharmaceutical Research's current Ending Cash Position is $1.47 Mil.
How does OWC Pharmaceutical Research's Ending Cash Position compare to PARNF and CANB?
OWC Pharmaceutical Research's Ending Cash Position of $1.47 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on OWC Pharmaceutical Research and its competitors. OWC Pharmaceutical Research's current Ending Cash Position is $1.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current Ending Cash Position of $1.47 Mil. The current Ending Cash Position is $1.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current Ending Cash Position is $1.47 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.